Edwards Lifesciences Corporation Restructuring and Related Cost, Expected Number of Positions Eliminated
Edwards Lifesciences Corporation (EW) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 360 employee for the 1-month period ending 2024-09-30, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2026-02-25
- 2024-09-30: Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month 360.00 employee.
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 1 month |
|---|---|
| 2024-09-30 | 360.00 employee 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |